Regeneron Pharmaceuticals Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 30, 2026 results vs estimates
Regeneron Pharmaceuticals Inc Forecast
Regeneron Pharmaceuticals Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 23.6% a year, a typical one-standard-deviation range is 791.51–846.03 over a week, 762.90–874.64 over a month and 625.22–1,012 over a year. (Signals as of 1 Nov 2026.)
Regeneron Pharmaceuticals Inc Price Chart
Regeneron Pharmaceuticals Inc Factors
YoY +1.4%
YoY −10.0%
YoY −1.4%
YoY −0.1%
YoY −10.6%
YoY −15.9%
YoY −1.4%
YoY —
YoY +6.7%
YoY +14.9%
YoY +8.3%
YoY −17.5%
YoY −13.3%
YoY −3.5%
YoY −7.5%
YoY +16.7%
YoY −6.5%
Regeneron Pharmaceuticals Inc fundamentals: income statement, balance sheet & cash flow
Regeneron Pharmaceuticals Inc reported revenue of $14.34bn and net income of $4.50bn in FY2025, the year ended 31 December 2025 — revenue up 1.0% and net income up 2.1% on the prior year. Free cash flow was $4.08bn. These figures are as reported in the filings, not restated: 36 fiscal years and 147 quarters of history, back to December 1990. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 14.34 | 14.20 | 13.12 | 12.17 | 16.07 |
| Cost of revenue | 2.10 | 1.97 | 0.88 | 1.71 | 2.72 |
| Gross profit | 12.24 | 12.23 | 12.23 | 10.47 | 13.35 |
| Research & development | 5.85 | 5.23 | 4.44 | 3.06 | 2.62 |
| Operating income | 3.58 | 3.99 | 4.05 | 4.74 | 8.95 |
| EBITDA | 5.82 | 5.32 | 4.05 | 5.26 | 9.67 |
| Interest expense | 0.04 | 0.06 | 0.07 | 0.06 | 0.06 |
| Pre-tax income | 5.23 | 4.78 | 4.20 | 4.86 | 9.33 |
| Income tax | 0.73 | 0.37 | 0.25 | 0.52 | 1.25 |
| Net income | 4.50 | 4.41 | 3.95 | 4.34 | 8.08 |
Download Regeneron Pharmaceuticals Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.REGN.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Regeneron Pharmaceuticals Inc
Explore MacroFinance macro & markets research and analysis.
Regeneron Pharmaceuticals Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Regeneron Pharmaceuticals Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Regeneron Pharmaceuticals Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Regeneron Pharmaceuticals Inc (United States)
Regeneron Pharmaceuticals Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Regeneron Pharmaceuticals Inc?
What is the latest Regeneron Pharmaceuticals Inc price?
Is Regeneron Pharmaceuticals Inc in an uptrend?
How volatile is Regeneron Pharmaceuticals Inc?
What factors affect Regeneron Pharmaceuticals Inc?
Which trading strategies trade Regeneron Pharmaceuticals Inc?
How are Regeneron Pharmaceuticals Inc returns analysed?
Where can I download free Regeneron Pharmaceuticals Inc historical data?
Free Regeneron Pharmaceuticals Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Regeneron Pharmaceuticals Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.REGN.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 920.69 |
| 2026-11-19 | 922.4 |
| 2026-11-18 | 944.567 |
| 2026-11-17 | 956.785 |
| 2026-11-16 | 951.43 |
| 2026-11-13 | 954.497 |
| 2026-11-12 | 950.222 |
| 2026-11-11 | 958.433 |
| 2026-11-10 | 915.127 |
| 2026-11-09 | 919.023 |
About this stock
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.